177Lu-PSMA-617cyclophosphamideCymetastatic castration-resistant prostate cancermetastatic castration-resistant prostate cancer (mCRPC)mCRPCRPTNCT03873805
…responses, and extended durability. By using the two therapies (177Lu-PSMA-617 and PSCA-CAR T cells) that are FDA approved or in clinical deve…